AZD 4619

Drug Profile

AZD 4619

Latest Information Update: 03 Apr 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antihyperlipidaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Lipid metabolism disorders

Most Recent Events

  • 02 Feb 2006 Discontinued - Phase-I for Lipid metabolism disorders in Europe (unspecified route)
  • 20 Jun 2005 This compound is still in active development
  • 22 Jul 2004 Phase-I clinical trials in Lipid metabolism disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top